Buy Factory Supply 00% High Purity CAS133737-32-3 Pagoclone From Lab of Wujiaren

Basic Information

Pagoclone is an anxiolytic agent from the cyclopyrrolone family, related to better-known drugs such as the sleeping medication zopeclone. It was synthesized by a French team working for Rhone-Poulenc & Rorer S.A. Pagoclone belongs to the class of nonbenzodiazepines, which have similar effects to the older benzodiazepine group, but with quite different chemical structures. It was never commercialised.

It binds with roughly equivalent high affinity (0.7-9.1 nM) to the benzodiazepine binding site of human GABA_A receptors containing either an α1, α2, α3 or α5 subunit. It is a partial agonist at α1-, α2- and α5-containing GABAA receptors and a full agonist at receptors containing an α3 subunit. In rats 5′-hydroxypagoclone was identified as a major metabolite. This metabolite has a considerably greater efficacy at the α1 subtype than the parent compound and was shown to have significant anxiolytic-like activity and to produce sedation. In contrast to zopeclone, pagoclone produces anxiolytic effects with little sedative or amnestic actions at low doses.

The pharmacologist David Nutt has suggested pagoclone as a possible base from which to make a better social drug, as it produces the positive effects of alcohol, such as relaxation and sociability, but without also causing the negative effects like aggression, amnesia, nausea, loss of coordination and liver damage. Its effect can be quickly reversed by the action of flumazenil, which is already used as an antidote to benzodiazepine overdose. Nutt has published studies praising the potential of pagoclone which were financed by Indevus which was seeking funding for a possible production of the compound. The long-term safety of pagoclone has not been assessed. The abuse potential of pagoclone has been assessed as being similar to, or slightly less than that of diaz pam and it would also be expected to be somewhat safer due to its relatively weaker sedative effects, but development of pagoclone as a commercial drug would still be unlikely due to concerns about abuse.

Pagoclone was trialed as a drug to improve a stammerer's speech fluency, but research for this application was discontinued following disappointing results in Phase II clinical trials.

Synthesis

Pagoclone and pazinaclone are both isoindolone:

Our Company
Wuhan Wujia Trading Co.,Ltd is a high-tech innovative enterprise specializingin the R & D, production and sales of API and pharmaceutical intermediates(excluding drugs). Our company is based on the optical valley biologicalcity, with the help of Wuhan University Scientific Research Laboratory,making full use of the park policy advantages, focusing on the researchand development of biological medicine. Our company always adheres to thebusiness philosophy of "market demand oriented; technology researchand development as the core competitiveness; e-commerce as the platform",more accurate, better, faster and more reliable to provide biomedical productsfor pharmaceutical units, university scientific research institutions,hospital outpatient service, reagent units, distributors in the world.